IL6R-α neutralization with tocilizumab does not alter the Treg/Th17 axis. (A) Representative contour plots of allogeneic Treg populations. Tregs were identified by gating on the moDC-stimulated allogeneic CD3⁺, CD4⁺, CD25^bright T cells, and then assessing for expression of Foxp3 and lack of CD127. (B) Bar graph depicts the means from 4 independent experiments (paired t test), ± SD, for the percentages of Tregs in alloMLRs treated with tocilizumab or control Ig (5ug/mL). (C) Effect of IL6R α inhibition on the ratio of CD4⁺ Tregs to CD8⁺CD25⁺ effector T cells in alloMLRs, compared with control. Bar graph shows means from 3 independent experiments, ± SD; NS = not significant, paired t test. (D) Representative contour plots of moDC-stimulated allogeneic Th1 and Th17 cells. Th1 and Th17 cells were identified by gating on the CD3⁺ CD4⁺ population and then evaluating for intracellular IFN-γ and IL17, respectively. (E) Bar graph shows means from 3 independent experiments, ± SD (paired t test, NS = not significant), representing the percentages of CD3⁺, CD4⁺, IFN-γ⁺ cells in the alloMLRs treated with tocilizumab (5 ug/mL) or control. (F) Bar graph shows means from 3 independent experiments, ± SD (paired t test, NS = not significant) for the percentages of CD3⁺, CD4⁺, IL17⁺ cells in the alloMLRs treated with tocilizumab (5 ug/mL final) or control.